6086.HK

Online healthcare platform Fangzhou Inc. (6086.HK) announced last Friday its revenue rose 11.2% last year to 2.71 billion yuan ($374 million). Its annual net loss widened from 197 million yuan in 2023 to 855 million yuan last year, but its adjusted net profit jumped 139% to 17.12 million yuan over that period.

During the reporting period, Fangzhou’s core businesses continued to post steady growth. Revenue from its online retail pharmacy service under the Fangzhou Jianke brand reached 1.41 billion yuan, up 8.3% year-on-year; and revenue from its customized content and marketing solutions rose 20.7% to 105 million yuan. Its chronic disease management platform added 6.5 million registered users during the year, raising the total from 42.7 million at the end of 2023 to 49.2 million at the end of last year. Average monthly active users grew 20% year-on-year to 10.1 million.

Last month, Fangzhou announced its integration of the open-source DeepSeek large language model into its systems, completing a privatized deployment. The company plans to focus on developing multiple AI assistant application scenarios in 2025 to drive practical implementation.

Fangzhou’s stock opened 8.1% higher at HK$5.86 on Monday, and has gained 47% over the past month.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Andre Juice sells juice concentrate

Andre Juice’s growth stalls after bumper period

China’s leading maker of apple juice concentrate reported its revenue contracted in the third quarter, ending a period of strong gains in the previous year and a half Key Takeaways:…
Fuyao Glass logs double digit growth

Fuyao Glass looks to new era as its founder bows out

The son of celebrated entrepreneur Cao Dewang has formally taken the helm at the automotive glass giant, just as the firm unveiled upbeat quarterly earnings Key Takeaway: The company logged…